Clinical Trial

Pioglitazone to Reduce Sympathetic Overactivity in CKD Patients

Terminated Phase 4
View on ClinicalTrials.gov →
Why the trial stopped
CKD participants we recruited do not have elevated ADMA, which is the main premise for this intervention. We noticed this with first cohort studied and collected blood from our other ongoing CKD studies, which further solidified and why terminated.
Summary
Chronic kidney disease (CKD) is associated with a higher risk of cardiovascular disease and death. An overactive sympathetic nervous system in CKD patients is one of the major mechanisms increasing the cardiovascular risks in this patient population. Recently, some studies have shown that a drug typically used to improve glucose control (pioglitazone) may also reduce sympathetic nerve activity and improve blood vessel function. The goal of this study is to determine whether a short-term treatment with pioglitazone can reduce sympathetic nerve impulses throughout the body in CKD patients.
Protocol Amendment History 6 changes
critical Trial terminated 2026-07-28
critical Trial terminated: CKD participants we recruited do not have elevated ADMA, which is the main premise for this intervention. We noticed th... 2026-07-28
critical Primary endpoint(s) modified 2026-07-28
notable Enrollment reduced: 28 -> 5 participants 2026-07-28
notable Primary completion moved earlier: 2026-04-01 -> 2020-01-14 2026-07-28
minor Completion moved earlier: 2026-04-01 -> 2020-01-14 2026-07-28
Trial Details
NCT Number NCT03471117
Lead Sponsor The University of Texas at Arlington
Collaborators: University of Texas, Southwestern Medical Center at Dallas
Conditions Chronic Kidney Diseases
Enrollment 5 participants
Start Date 2018-04-01
Primary Completion 2020-01-14 (estimated)
Study Completion 2020-01-14 (estimated)
Updated on ClinicalTrials.gov 2026-07-27